The Wireless Power Management Consortium (WPM-c) has announced a strategic support program for Helioverse Innovations, Inc., the U.S. venture working to commercialize fully implantable, wireless-powered artificial heart technology and related implantable devices.

WPM-c — an industry consortium that promotes the practical adoption and co-creation of wireless power technologies, including Japan’s DC-resonance approach — will provide organizational backing and collaboration channels intended to accelerate Helioverse’s technology validation and market entry.

According to WPM-c’s announcement, the support program aims to help Helioverse scale its activities from research and prototype verification toward broader industrialization and global deployment. The consortium highlighted that Helioverse’s work builds on years of clinical and translational R&D led by cardiac surgeon Dr. Taiyo Kuroda, including research conducted at the Cleveland Clinic.

This partnership is framed as a co-creation effort: WPM-c will connect Helioverse with member organizations, technical experts, and IP/licensing resources to help resolve practical engineering and implementation challenges around wireless power for implantables. WPM-c said these joint activities will contribute to both safer, patient-centric medical solutions and the broader industrial ecosystem for wireless power.

Helioverse and WPM-c plan to publish progress updates as collaborative milestones are reached and to explore technical demonstrations and pilot projects with consortium members.

For more information about WPM-c and its activities, see: https://wpm-c.com/?page_id=274